Amendment (g) Unblinded Extension Phase of Somatropin in Patients With Idiopathic Short Stature
After approval of amendment (g), patients who were still receiving study drug at the time were scheduled for a study visit. In addition, patients who had discontinued early from the core, blinded phase of the study were contacted.
All of these patients were offered the opportunity to enter the unblinded extension phase (if they met eligibility criteria) and continue somatropin treatment (regardless of initial treatment randomization) until they reached final height.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase III Study of Humatrope in Non-Growth Hormone Deficient Children With Short Stature|
- Every 6 months: physical exam, pubertal staging, height, weight, and adverse event collection.
- Every year: arm span measurements, head circumference measurements, x-ray for bone age, and
- laboratory blood draws.
- Not applicable for Amendment (g).
|Study Start Date:||February 2001|
|Estimated Study Completion Date:||January 2006|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00191074
|United States, Maryland|
|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.|
|Bethesda, Maryland, United States, 20892|
|Study Director:||Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)||Eli Lilly and Company|